Citation Impact
Citing Papers
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression
2005 StandoutNobel
CD4+ Count–Guided Interruption of Antiretroviral Treatment
2006 Standout
Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
2011
PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
2008
EGFR Antagonists in Cancer Treatment
2008 Standout
Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
1997
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
2013 StandoutNature
Role for the p53 homologue p73 in E2F-1-induced apoptosis
2000 StandoutNatureNobel
Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow-up
1995
p53, the Cellular Gatekeeper for Growth and Division
1997 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Lung Cancer
2008 Standout
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer
2005
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
2013
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
1996 StandoutNature
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
2005 StandoutNature
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth
1997 Standout
Role of the retinoblastoma protein in the pathogenesis of human cancer.
1997 StandoutNobel
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Retinoids in cancer therapy.
1992
WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis
2009
Interferon treatment of cutaneous T‐cell lymphoma
1993
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia.
1992
Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8
2001
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
Wnt/β-Catenin Signaling and Disease
2012 Standout
Epidemiology of Lung Cancer
2013
Multifactorial analysis of p53 alteration in human cancer: A review
1994
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a
1997 Standout
Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression
2001
Treatment of Cutaneous T Cell Lymphoma
2002
A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
1994 StandoutScience
Infectious and immunosuppressive complications of purine analog therapy.
1995
A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer
2000
E2F-1 Functions in Mice to Promote Apoptosis and Suppress Proliferation
1996 StandoutNobel
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis
1999 StandoutNobel
Therapy of Cutaneous Lymphoma – Current Practice and Future Developments
2003
Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas
2003
Tumour suppression by the human von Hippel-Lindau gene product
1995 StandoutNobel
Head and Neck Cancer
1993 Standout
Primary Cutaneous T-Cell Lymphomas
2006
Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy
1992
Sézary syndrome: Diagnosis, prognosis, and critical review of treatment options
1990
Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes
2003 Standout
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
1993 Standout
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
1994 Standout
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation
2000 StandoutNatureNobel
High-Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR
1994 Science
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
EMERGING NEW THERAPIES FOR CUTANEOUS T-CELL LYMPHOMA
2000
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
The tumore suppressor p53
1993
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
2017 Standout
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis.
1997
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Peripheral T- cell lymphomas: diagnosis and management
2003
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
1999 StandoutNobel
Mechanisms of DNA Excision Repair
1994 StandoutScienceNobel
Cancer Cell Cycles
1996 StandoutScience
Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma
2003
Cell Cycle Control and Cancer
1994 StandoutScienceNobel
EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.
1997 Standout
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
2003
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
2005
Interferon in the Treatment of Cutaneous T-cell Lymphoma
1995
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.
1998
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
2003
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
1995 Standout
The retinoblastoma protein and cell cycle control
1995 Standout
Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
2005
Cancer Genome Landscapes
2013 StandoutScience
Determination of the Structures of Symmetric Protein Oligomers from NMR Chemical Shifts and Residual Dipolar Couplings
2011 StandoutNobel
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.
1994 StandoutNobel
Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers.
1993
Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis
1998
Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis
1998
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
1994 StandoutScience
Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
2005 StandoutNobel
Works of Ruby Phelps being referenced
Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years.
1990
Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
1990
NCI-navy medical oncology branch cell line data base
1996
A Randomized Trial Comparing Combination Electron-Beam Radiation and Chemotherapy with Topical Therapy in the Initial Treatment of Mycosis Fungoides
1989
Rates and Risk Factors for Condition-Specific Hospitalizations in HIV-Infected and Uninfected Women
2003
Cancer incidence in women with or at risk for HIV
2001
Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
1992
High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors
1993
ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.
1991